{
    "eid": "2-s2.0-85135252228",
    "title": "Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine",
    "cover-date": "2022-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Immunology",
            "@code": "2403",
            "@abbrev": "IMMU"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Drug Discovery",
            "@code": "3002",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Infectious Diseases",
            "@code": "2725",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology (medical)",
            "@code": "2736",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "BBIBP-CorV",
        "inactivated vaccine",
        "mRNA vaccine",
        "third dose",
        "viral vector vaccine"
    ],
    "authors": [
        "Jira Chansaenroj",
        "Nungruthai Suntronwong",
        "Sitthichai Kanokudom",
        "Suvichada Assawakosri",
        "Ritthideach Yorsaeng",
        "Preeyaporn Vichaiwattana",
        "Sirapa Klinfueng",
        "Lakana Wongsrisang",
        "Donchida Srimuan",
        "Thaksaporn Thatsanatorn",
        "Thanunrat Thongmee",
        "Chompoonut Auphimai",
        "Pornjarim Nilyanimit",
        "Nasamon Wanlapakorn",
        "Natthinee Sudhinaraset",
        "Yong Poovorawan"
    ],
    "citedby-count": 10,
    "ref-count": 37,
    "ref-list": [
        "Clinical course and mortality risk of severe COVID-19",
        "Confronting the Delta Variant of SARS-CoV-2, Summer 2021",
        "China\u2019s COVID vaccines have been crucial\u2014now immunity is waning",
        "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults",
        "Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2",
        "SARS-CoV-2 Post Vaccinated Adverse Effects and Efficacy in the Egyptian Population",
        "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: A randomised, double-blind, placebo-controlled, phase 1/2 trial",
        "COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development",
        "Public awareness about coronavirus vaccine, vaccine acceptance, and hesitancy",
        "Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar",
        "Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant",
        "Impact of the Sinopharm\u2019s BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE)",
        "SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance",
        "Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study",
        "Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants",
        "Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19\u2013Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance\u2014 VISION Network, 10 States, August 2021\u2013January 2022",
        "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial",
        "Safety and Immunogenicity of a Recombinant Adenovirus Type-5\u2013Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged \u22656 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial",
        "Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant",
        "Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar",
        "Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel",
        "Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy",
        "Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine",
        "An mRNA Vaccine against SARS-CoV-2\u2014Preliminary Report",
        "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine",
        "Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults",
        "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2\u2013spike protein\u2013protein interaction",
        "Humoral immune response of BBIBP COVID-19 vaccination before and after the booster immunization",
        "Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study",
        "COVID-19 Vaccine: Side Effects After the First Dose of the Oxford AstraZeneca Vaccine Among Health Professionals in Low-Income Country: Ethiopia",
        "Side Effects and Perceptions Following COVID-19 Vaccination in Jordan: A Randomized, Cross-Sectional Study Implementing Machine Learning for Predicting Severity of Side Effects",
        "Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination",
        "Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial",
        "Safety and immunogenicity of a third-dose homologous BBIBP-CorV boosting vaccination: Interim results from a prospective open-label study",
        "Investigation and long-term monitoring of the presence of neutralizing antibody in patients with COVID-19 disease of different clinical severity",
        "Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents",
        "Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "127614853",
            "affilname": "The Royal Society of Thailand (FRS(T))",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127614853",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Center of Excellence in Clinical Virology of Chulalongkorn University/King Chulalongkorn Memorial Hospital",
        "Second Century Fund",
        "Chulalongkorn University",
        "National Research Council of Thailand",
        "Health Systems Research Institute"
    ]
}